Skip to content

BBNX BBNX Additional Paid-In Capital

Additional Paid-In Capital at other companies

Insulet logo
InsuletPODD
$1.28B+1.6%
Tandem Diabetes Care logo
Tandem Diabetes CareTNDM
$1.4B+5.0%
Medtronic logo
MedtronicMDT
$20.93B+0.4%
AdaptHealth logo
AdaptHealthAHCO
$2.18B+0.9%
Halozyme Therapeutics logo
Halozyme TherapeuticsHALO
$27.39M+261%

Other financials

Income statement

See full
Revenue$27.6M+56.6%
Gross profit$16.4M+83.2%
Operating income-$24.3M-30.2%
Net income-$21.9M+23.6%
EPS (diluted)-$0.49+47.3%

Balance sheet

See full
Cash & equivalents$30.2M-28.9%
Total debt$6.9M-0.9%
Total equity$271.2M-13.5%
Total assets$304.4M-9.9%

Cash flow

See full
Operating cash flow-$23.8M-19.3%
CapEx$1.4M+314%
Free cash flow-$25.2M-24.1%

Valuation

See full
Market cap$708.98M-8.6%
Enterprise value$685.68M
P/S6.4×

Profitability

See full
Gross margin57.2%+3.2pp
Operating margin-70.1%-6.4pp
Net margin-60.3%-17.4pp
FCF margin-55.4%-14.3pp

Returns & leverage

See full
Return on equity-22.7%
Debt / equity0.0×
Current ratio10.7×-5.2×

Where this comes from

Reported directly by BBNX in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.

The official record: BBNX’s 10-Q, filed April 21, 2026, on SEC EDGAR. View the filing →

Ask your AI about BBNX's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BBNX's additional paid-in capital?
BBNX (BBNX) reported additional paid-in capital of $663.17M in Q1 2026.
How has BBNX's additional paid-in capital changed year-over-year?
BBNX's additional paid-in capital increased by 3.8% year-over-year, from $638.9M to $663.17M.
What is the long-term trend for BBNX's additional paid-in capital?
Over 2 years (2023 to 2025), BBNX's additional paid-in capital has grown at a 398.7% compound annual growth rate (CAGR), from $26.42M to $657.14M.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.